Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNK | O75909 | 5/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 5/20 | 0.40 |
| ▸ | KDM5A | P29375 | 4/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4583904 | 0.97 | CCNK (0.42) | CCNKCDK12KDM5AMCHR1F10 | |
| SCHEMBL4583390 | 0.89 | CCNK (0.43) | CCNKCDK12KDM5AMCHR1F10 | |
| SCHEMBL4583666 | 0.89 | CCNK (0.43) | CCNKCDK12KDM5AMCHR1F10 | |
| SCHEMBL4584030 | 0.89 | CCNK (0.43) | CCNKCDK12KDM5AMCHR1F10 | |
| SCHEMBL4582426 | 0.86 | CCNK (0.46) | CCNKCDK12KDM5AMCHR1F10 | |
| SCHEMBL4584327 | 0.86 | CCNK (0.46) | CCNKCDK12KDM5AMCHR1F10 | |
| SCHEMBL4584897 | 0.86 | CCNK (0.46) | CCNKCDK12KDM5AMCHR1F10 | |
| SCHEMBL4582199 | 0.85 | CCNK (0.46) | CCNKCDK12KDM5AMCHR1F10 | |
| SCHEMBL3306214 | 0.85 | ALDH1A1 (0.47) | CCNKCDK12KDM5AF10HDAC6 | |
| SCHEMBL4582991 | 0.84 | CCNK (0.42) | CCNKCDK12KDM5AMCHR1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1975165-A1 | Substituted pyrrolidinamides, their production and utilisation as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2008-10-01 | — | — | EP | disclosed |